Debate On Patient-Focused Biologic Design To Be Led By Catalent At Drug Delivery Partnerships

SOMERSET, N.J. – January 24, 2019 — Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Cornell Stamoran, Ph.D., Vice President of Strategy and Co-chair of the Catalent Applied Drug Delivery Institute, will present at the 23rd annual Drug Delivery Partnerships (DDP) conference at the PGA National Resort & Spa, Palm Beach Gardens, Florida on Jan. 28 – 30, 2019.

On Monday, Jan. 28 at 2:15 p.m., Dr. Stamoran will moderate a panel discussion entitled “Design and Perspective on Biologics Treatments” in the “Strategies and Insights: Patient-Centric Design and Development Principles” track. Joining Dr. Stamoran will be Advait Badkar, Ph.D., who leads the Novel Delivery Technologies group within Pfizer’s Biotherapeutics Pharmaceutical Sciences organization, and Uri Baruch, a partner at Cambridge Design Partnership who leads their drug delivery practice. The panel will discuss challenges and opportunities in improving administration of antibodies and other large molecule biologics by applying patient-focused design principles to formulation, dose form and device selection. Dr. Stamoran will also chair the afternoon-long Patient-Centric content track.

Outpatient-administered biologics are still a relatively new treatment modality and many patients and supporting caregivers are unfamiliar with their use, leading to potential administration errors, poor adherence, and sub-therapeutic outcomes. By more deeply understanding real-world patient behaviors, we can design biologic products with improved patient utility, which then can lead to improved real-world outcomes,” says Dr. Stamoran.

Dr. Stamoran leads Catalent’s strategic planning, market intelligence and government affairs efforts. He has spent nearly 30 years engaged with the health care industry, including more than 25 years in advanced drug and biologic delivery and outsourcing. In 2012, Dr. Stamoran founded the Catalent Applied Drug Delivery Institute, whose mission is to educate and advocate for the enhanced use of drug delivery technologies to improve patient outcomes. 

For more information visit

 To arrange a meeting with Dr. Stamoran at the event, contact Richard Kerns at NEPR -

Media Contacts:

Chris Halling
+44 (0)7580 041073

Richard Kerns
+44 (0)161 728 5880

About the Catalent Applied Drug Delivery Institute

Catalent’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies.For more details on the Catalent Institute, visit and follow the Catalent Institute on Twitter: @DrugDeliveryIns

About Catalent

Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs over 11,000 people, including over 1,800 scientists, at more than 30 facilities across five continents, and in fiscal 2018 generated approximately $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit

More products. Better treatments. Reliably supplied.™